Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT02829268
First received: July 6, 2016
Last updated: March 24, 2017
Last verified: March 2017
  Purpose

Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.


Condition Intervention Phase
Wolfram Syndrome
Diabetes Mellitus
Optic Nerve Atrophy
Ataxia
Drug: dantrolene sodium
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Number of participants with treatment-related adverse events as assessed by liver function tests [ Time Frame: 6 months ]

    The investigators assess the safety and tolerability of dantrolene sodium administered orally at upper end of therapeutic dose range for 6 months in patients with Wolfram syndrome. More specifically, the investigators perform liver function tests to check the levels of certain enzymes and proteins in participants' blood. Levels that are higher or lower than normal can indicate liver problems. The liver function tests include:

    Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline Phosphatase (AP), and bilirubin.



Secondary Outcome Measures:
  • Changes in C-peptide levels in participants assessed by the ELISA assay [ Time Frame: 6 months ]
    The investigators determine the effect of dantrolene sodium on residual beta cell functions. The investigators monitor base-line C-peptide levels in participants' blood. The investigators also monitor C-peptide levels in participant's blood during the oral mixed meal tolerance test. The night before the oral mixed meal tolerance test, the participants will turn their insulin pump basal rate to 50% of the normal rate at midnight or take half of their evening dose of Lantus insulin and fasted from midnight until the test at 8 a.m. The mixed meal consists of 6 ml/kg (maximum 360 ml) of Boost Original (Société des Produits Nestlé S.A., Vevey, Switzerland). Blood for glucose and C-peptide measurement will be drawn at time 0 (fasting) and 30 minutes after the Boost. If a subject's fasting glucose exceeds 11.1 mmol/l, the test will not be performed, but fasting glucose and C-peptide will be obtained.

  • Changes in Visual Functioning in participants assessed by Visual Functioning Questionnaire-25. [ Time Frame: 6 months ]
    Visual functions will be assessed by Visual Functioning Questionnaire - 25.

  • Changes in best-corrected visual acuity in participants measured by Snellen optotype [ Time Frame: 6 months ]
    Best-corrected visual acuity will be measured by Snellen optotype. Higher logMar scores indicate worse vision.

  • Changes in Neurological Functions in participants assessed by the Wolfram Unified Rating Scale (WURS) [ Time Frame: 6 months ]
    Neurological functions will be assessed by the Wolfram Unified Rating Scale (WURS) and standard neurological assessments.


Estimated Enrollment: 50
Actual Study Start Date: January 2017
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pediatric
Pediatric patients treated with dantrolene sodium
Drug: dantrolene sodium

The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

Experimental: Adult
Adult patients treated with dantrolene sodium
Drug: dantrolene sodium

The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.


  Eligibility

Ages Eligible for Study:   5 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for enrolment:

  1. The patient has a definitive diagnosis of Wolfram syndrome, as determined by the following:

    a. Documented functionally relevant recessive mutations on both alleles of the WFS1 gene or dominant mutation on one allele of the WFS1 gene based on historical test results (if available) or from a qualified laboratory at screening.

  2. The patient is at least 5 years of age (biological age) at the time of written informed consent.
  3. The patient, patient's parent(s), or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient. The guardians' consent and patient's assent, as relevant, must be obtained.

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for this study:

  1. The patient has clinically significant non-Wolfram related CNS involvement which is judged by the investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.
  2. The patient has a known defect in oxidative phosphorylation (such as a confirmed mitochondrial myopathy)
  3. The patient has abnormal liver function (defined as serum transaminases more than twice the upper limit of normal for the reference laboratory)
  4. The patient has a significant medical or psychiatric co-morbidity that might affect study data or confound the integrity of study results.
  5. The patient has received treatment with any investigational drug within the 30 days prior to study entry.
  6. The patient has received blood product transfusions within 90 days prior to screening.
  7. The patient is unable to comply with the protocol, (e.g. has a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioural instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.
  8. The patient has a known history of central apnea and/or ventilation requirements.
  9. The patient has a known history of chronic obstructive pulmonary disease, pleural effusion, and/or myocardial disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02829268

Contacts
Contact: Ashley N Simpson, RN, BSN, CPN +1-314-286-1550 ashley.simpson@wustl.edu
Contact: Teresa Arb, RN, BSN, CCRC +1-314-747-1217 arbt@wustl.edu

Locations
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Ashley Simpson, RN, BSN, CPN    314-286-1550    ashley.simpson@wustl.edu   
Contact: Fumihiko Urano, MD    314-362-8683    urano@wustl.edu   
Principal Investigator: Fumihiko Urano, MD         
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Study Director: Fumihiko Urano, MD Washington University School of Medicine
  More Information

Additional Information:
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT02829268     History of Changes
Other Study ID Numbers: 201607006
Study First Received: July 6, 2016
Last Updated: March 24, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: publication

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Washington University School of Medicine:
Wolfram syndrome
Diabetes Mellitus
Optic Nerve Atrophy
Ataxia
Endoplasmic Reticulum Stress

Additional relevant MeSH terms:
Syndrome
Diabetes Mellitus
Atrophy
Ataxia
Optic Atrophy
Wolfram Syndrome
Disease
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathological Conditions, Anatomical
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Deaf-Blind Disorders
Deafness
Hearing Loss
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Optic Atrophies, Hereditary
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Sensation Disorders
Blindness

ClinicalTrials.gov processed this record on May 24, 2017